Erratum: Mechanism of MEK inhibition determines efficacy in mutant KRAS-versus BRAF-driven cancers (Nature (2013) 501 (232-236) DOI:10.1038/nature12441);Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

Nature

Volumn 501, Issue 7466, 2013, Pages 232-236

  Hatzivassiliou, Georgia ^a   Haling, Jacob R ^a   Chen, Huifen ^a   Song, Kyung ^a   Price, Steve ^b   Heald, Robert ^b   Hewitt, Joanne F M ^b,c   Zak, Mark ^a   Peck, Ariana ^a,d   Orr, Christine ^a   Merchant, Mark ^a   Hoeflich, Klaus P ^a   Chan, Jocelyn ^a   Luoh, Shiuh Ming ^a   Anderson, Daniel J ^a,g   Ludlam, Mary J C ^a,f   Wiesmann, Christian ^a,e   Ultsch, Mark ^a   Friedman, Lori S ^a   Malek, Shiva ^a   Belvin, Marcia ^a   more..

^a GENENTECH INC   (United States)

^b Argenta Discovery Ltd   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e NOVARTIS PHARMA AG   (Switzerland)

^f Cairn Biosciences Inc   (United States)

^g Cleave Biosciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; COBIMETINIB; G 573; GDC 0623; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

DISEASE; GENOTYPE; MUTATION; PROTEIN; TUMOR;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; GENE MUTATION; GENOTYPE; HUMAN; HYDROGEN BOND; NONHUMAN; PRIORITY JOURNAL;

EID: 84884127318     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature12659     Document Type: Erratum

References (29)

1. Akinleye, A., Furqan, M.,Mukhi, N., Ravella, P.&Liu, D.MEK and the inhibitors: from bench to bedside. J. Hematol. Oncol. 6, 27 (2013).
2. Blasco, R. B. et al. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 19, 652-663 (2011).
3. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
4. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nature Rev. Cancer 3, 11-22 (2003).
5. Bamford, S. et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br. J. Cancer 91, 355-358 (2004).
6. Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435 (2010).
7. Heidorn, S. J. et al. Kinase-deadBRAF andoncogenicRAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
8. Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430 (2010).
9. Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362 (2006).
10. Wellbrock, C., Karasarides, M. & Marais, R. The RAF proteins take centre stage. Nature Rev. Mol. Cell Biol. 5, 875-885 (2004).
11. Chapman, M. S. & Miner, J. N. Novel mitogen-activated protein kinase kinase inhibitors. Expert Opin. Investig. Drugs 20, 209-220 (2011).
12. Engelman, J. A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nature Med. 14, 1351-1356 (2008).
13. is an inhibitor ofMEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin. Cancer Res. 17, 989-1000 (2011).
14. Hoeflich, K. P. et al. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res. 72, 210-219 (2012).
15. Friday, B. B. et al. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res. 68, 6145-6153 (2008).
16. Pratilas, C. A. et al. V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl Acad. Sci. USA 106, 4519-4524 (2009).
17. Delaney, A. M., Printen, J. A., Chen, H., Fauman, E. B.& Dudley, D. T. Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352. Mol. Cell. Biol. 22, 7593-7602 (2002).
18. Heald, R. A. et al. Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactions. J. Med. Chem. 55, 4594-4604 (2012).
19. OHagan, D. Understanding organofluorine chemistry. An introduction to the C-F bond. Chem. Soc. Rev. 37, 308-319 (2008).
20. Gopalbhai, K. et al. Negative regulation of MAPKK by phosphorylation of a conserved serine residue equivalent to Ser212 of MEK1. J. Biol. Chem. 278, 8118-8125 (2003).
21. Sheth, P. R. et al. Fully activatedMEK1 exhibits compromised affinity for binding of allosteric inhibitors U0126 and PD0325901. Biochemistry 50, 7964-7976 (2011).
22. Resing, K. A. & Ahn, N. G. Deuterium exchange mass spectrometry as a probe of protein kinase activation. Analysis of wild-type and constitutively activemutants of MAP kinase kinase-1. Biochemistry 37, 463-475 (1998).
23. Rice, K. D. et al. Novel carboxamide-based allosteric MEK inhibitors: discovery and optimization efforts toward XL518 (GDC-0973). ACS Med. Chem. Lett. 3, 416-421 (2012)
24. Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T. & Saltiel, A. R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270, 27489-27494 (1995).
25. Ohren, J. F. et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nature Struct. Mol. Biol. 11, 1192-1197 (2004).
26. Garnett, M. J., Rana, S., Paterson, H., Barford, D. & Marais, R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 20, 963-969 (2005).
27. Ro ring, M. et al. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO J. 31, 2629-2647 (2012).
28. Rosen, L. et al. A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors. Cancer Res. 71, 4716 (2011).
29. Choo, E. F. et al. Preclinical disposition and pharmacokinetics- pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor. Xenobiotica 40, 751-762 (2010).